Regeneron Pharmaceuticals' Cash from Financing Activities rose 3129.9% to -$780.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$3.7 billion, marking a year-over-year decrease of 6884.34%. This contributed to the annual value of -$3.7 billion for FY2025, which is 6884.34% down from last year.
According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Cash from Financing Activities is -$780.1 million, which was up 3129.9% from -$717.9 million recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Cash from Financing Activities ranged from a high of $385.4 million in Q3 2021 and a low of -$1.1 billion during Q4 2024
Over the past 5 years, Regeneron Pharmaceuticals' median Cash from Financing Activities value was -$462.1 million (recorded in 2023), while the average stood at -$486.0 million.
Its Cash from Financing Activities has fluctuated over the past 5 years, first surged by 11765.83% in 2022, then plummeted by 241252.65% in 2025.
Regeneron Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$906.6 million in 2021, then skyrocketed by 72.69% to -$247.6 million in 2022, then tumbled by 80.17% to -$446.1 million in 2023, then tumbled by 154.54% to -$1.1 billion in 2024, then soared by 31.3% to -$780.1 million in 2025.
Its last three reported values are -$780.1 million in Q4 2025, -$717.9 million for Q3 2025, and -$1.1 billion during Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value